echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > FDA approves first Ebola treatment

    FDA approves first Ebola treatment

    • Last Update: 2021-03-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    October 14, local time, the U.S. Food and Drug Administration (FDA) approved the launch of Regeneron's medium-antibody cocktail therapy Inmazeb for the treatment of Ebola virus infection in adults and children. This is the first FDA-approved drug to treat Ebola virus infection.Ebola virus is a severe infectious disease virus that causes Ebola haemorrhagic fever in humans and other primates and can be transmitted through the blood, body fluids, secretions, excreta and pollutants of infected patients and infected animals, with a mortality rate of 50-90%.Although the FDA approved the first Ebola vaccine, Ervebo, in December 2019, there is still a gap in the field of therapeutic drugs. Redsiway, which was used to treat the Ebola virus in 2018 because of the new crown pneumonia treatment fire, was not approved by the FDA because of its relatively poor efficacy.The approved inmazeb is a new antiviral antibody drug once known as REGN-EB3. The drug consists of three similarly structured monoclonal antibodies, atoltivimab, maftivimab, and odesivimab-ebgn, which prevents the invasion of the human body by targeting glycoproteins on the surface of the Ebola virus.In a deep vein-flow trial launched in 2018 covering 681 Ebola patients, Inmazeb's safety and effectiveness were validated, with about one-third of those receiving the treatment die after 28 days, compared with about half of those in the control group. The report was published on NEJM in December 2019.Currently, Inmazeb has been recognized as an "orphan drug" and the FDA has awarded it a breakthrough therapy.FDA Commissioner Stephen M. Hahn said, "Inmazeb's approval demonstrates the FDA's continued commitment to responding to public health threats at home and abroad on the basis of science and data, and as part of its public health mission, the FDA is committed to promoting the development of safe and effective infectious disease treatments." Thethe U.S. government has funded the drug's development and plans to buy thousands of doses over the next six years for use in national strategic reserves. (Biological Exploration):1.2.REGENERON'S ANTIBODY COCKTAIL REGN-EB3 (INMAZEB®) IS FIRST FDA-APPROVED TREATMENT FOR EBOLA (ZAIRE EBOLAVIRUS).
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.